Home » Stocks » ACRX

AcelRx Pharmaceuticals, Inc. (ACRX)

Stock Price: $1.77 USD -0.02 (-0.84%)
Updated Oct 29, 2020 10:16 AM EDT - Market open

Stock Price Chart

Key Info

Market Cap 159.42M
Revenue (ttm) 4.39M
Net Income (ttm) -49.69M
Shares Out 90.32M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 29, 2020
Last Price $1.77
Previous Close $1.78
Change ($) -0.02
Change (%) -0.84%
Day's Open 1.75
Day's Range 1.71 - 1.80
Day's Volume 193,907
52-Week Range 0.70 - 2.50

More Stats

Market Cap 159.42M
Enterprise Value 145.94M
Earnings Date (est) Mar 11, 2021
Ex-Dividend Date n/a
Shares Outstanding 90.32M
Float 87.79M
EPS (basic) -0.62
EPS (diluted) -0.62
FCF / Share -0.64
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8.28M
Short Ratio 2.98
Short % of Float 9.43%
Beta 1.68
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 36.29
PB Ratio n/a
Revenue 4.39M
Operating Income -51.21M
Net Income -49.69M
Free Cash Flow -51.53M
Net Cash 13.49M
Net Cash / Share 0.15
Gross Margin -208.92%
Operating Margin -1,165.67%
Profit Margin -1,131.00%
FCF Margin -1,172.89%
ROA -34.25%
ROE n/a
ROIC -58.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 1

Analyst Consensus: Buy

Price Target

(181.59% upside)
Current: $1.77
Target: 4.97
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth6.42%-73.1%-53.94%-9.89%269.24%-82.32%1132.33%123.32%--
Gross Profit-4.52-1.83-2.665.0417.495.2229.502.391.07-
Operating Income-54.21-35.73-38.68-31.96-19.95-37.65-6.67-29.71-19.35-12.19
Net Income-53.24-47.15-51.51-43.16-24.40-33.35-23.43-33.36-20.10-14.34
Shares Outstanding79.1858.4146.8845.3144.3043.4339.7522.1217.340.66
Earnings Per Share-0.67-0.81-1.10-0.95-0.60-0.91-0.59-1.51-1.16-21.84
Operating Cash Flow-51.18-29.08-29.77-29.40-19.95-34.46-0.49-24.58-15.29-12.23
Capital Expenditures-3.47-0.82-2.41-3.72-1.46-5.51-3.29-0.83-2.02-
Free Cash Flow-54.65-29.89-32.17-33.12-21.41-39.96-3.77-25.41-17.31-12.23
Cash & Equivalents66.1410660.6580.4911475.6010459.9735.993.89
Total Debt29.7611.9919.1021.5520.9224.8714.3615.9719.0812.01
Net Cash / Debt36.3893.7241.5558.9492.7250.7389.5544.0016.91-8.12
Book Value-41.424.25-36.51-5.3433.1146.6673.1633.8517.47-65.89
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name AcelRx Pharmaceuticals, Inc.
Country United States
Employees 54
CEO Vincent J. Angotti

Stock Information

Ticker Symbol ACRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ACRX
IPO Date February 14, 2011


AcelRx Pharmaceuticals, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.